Brophy O'Connor Will Take Over Zeiss Meditec on December 1

Your daily brief on leadership and business

Bronwyn Brophy O'Connor will become CEO of Carl Zeiss Meditec AG on December 1, 2026. Carl Zeiss Meditec announced the start date on Monday. She currently runs the Vitrolife Group in Sweden.

On the same day she joins the Executive Board of Carl Zeiss AG, with responsibility for the Medical Technology segment. The company first announced her appointment in May.

She takes over from Andreas Pecher, who has been interim CEO of Carl Zeiss Meditec since January 1, 2026. Pecher is also President and CEO of Carl Zeiss AG, and the company calls it a temporary dual role.

"I am delighted to join Carl Zeiss Meditec and the ZEISS Group," Brophy O'Connor said. She said she looks forward to working with the teams and customers to build on the company's strengths and shape the next stage of its transformation.

Peter Kameritsch, chairman of the Carl Zeiss Meditec supervisory board, said the company is gaining an internationally experienced medtech executive with a strong customer and innovation perspective. Michael Bolle, chairman of the supervisory board of Carl Zeiss AG, thanked Pecher for giving the company important momentum during the interim period.

The leadership lineup from December

From December 1, the Carl Zeiss Meditec management board will consist of Brophy O'Connor as CEO and Justus Wehmer as CFO. The Carl Zeiss AG executive board will have six members: Pecher, Stefan Müller as CFO, Brophy O'Connor for Medical Technology, Sven Hermann for Consumer Markets, Frank Rohmund for Semiconductor Manufacturing Technology, and Marc Wawerla for Industrial Quality and Research.

Her career so far

Brophy O'Connor studied at Dublin City University and completed an MBA in 2002. She started at Johnson & Johnson in 1997 and left in 2012 as General Manager of its Cardiovascular Care Group for the U.K. and Ireland.

She then joined Covidien, later acquired by Medtronic. From 2013 to 2018 she was Vice President Early Technologies EMEA and later President Women's Health at Medtronic in Boston. In 2019 she became EMEA President at Thermo Fisher Scientific, and a year later Global President of its Immunodiagnostics Division in Uppsala, Sweden.

She has been CEO of Vitrolife, which is listed on Nasdaq Stockholm and based in Gothenburg, since 2023.

Source: Carl Zeiss Meditec